The law normally requires people who offer financial products to give information to investors before they invest. This information is designed to help investors make an informed decision.
If you are a wholesale investor under the definition of that term in clause 3 of Part 1 Schedule 1 of the Financial Markets Conduct Act 2013, the usual rules do not apply to offers of financial products made to you. As a result, you may not receive a complete and balanced set of information.
You will also have fewer other legal protections for these investments. Ask questions, read all documents carefully, and seek independent financial advice before committing yourself.
MARS Bioimaging has developed a breakthrough CT Scanner providing high resolution diagnostic imaging that is superior to traditional scanner at the point of care, resulting in:
- Higher throughput across the health system including hospitals, clinics and surgeries – initially targeting the US Market
- Higher quality, lower cost per image for all stakeholders: public, private, insurers, patients.
- Lower capital and operating costs for public and private care providers.
- Smaller footprint, easy to operate, at the point of care.
- Best-in-class pre-and-post-operative CT diagnostic imaging early in the care pathway.
MARS is raising capital to complete FDA compliance and support its launch in the US. They have partnered with HSS in the US and the equipment is being used currently as part of clinical trials. HSS has been ranked the top hospital for orthopaedics for 14 consecutive years by U.S. News & World Report (2023-2024) and is the oldest orthopaedic hospital in the US, with more than 32,000 surgical procedures performed annually. For further information click the register interest button below to access the webinar.
Pacific Channel one of New Zealand's leading VC's has committed $4.5m to this Kiwi technology disruptor alongside other institutional investors including HSS.
